Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Cash & Equivalents (2023 - 2026)

MBX Biosciences has reported Cash & Equivalents over the past 4 years, most recently at $45.2 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $45.2 million for Q1 2026, up 51.2% from a year ago — trailing twelve months through Mar 2026 was $45.2 million (up 51.2% YoY), and the annual figure for FY2025 was $75.3 million, up 52.56%.
  • Cash & Equivalents reached $45.2 million in Q1 2026 per MBX's latest filing, down from $75.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $223.1 million in Q3 2025 and bottomed at $29.9 million in Q1 2025.
  • Median Cash & Equivalents over the past 4 years was $47.3 million (2024), compared with a mean of $78.3 million.
  • The largest annual shift saw Cash & Equivalents soared 67.93% in 2025 before it soared 51.2% in 2026.
  • Over 4 years, Cash & Equivalents stood at $30.5 million in 2023, then soared by 61.68% to $49.4 million in 2024, then soared by 52.56% to $75.3 million in 2025, then tumbled by 39.95% to $45.2 million in 2026.
  • Business Quant data shows Cash & Equivalents for MBX at $45.2 million in Q1 2026, $75.3 million in Q4 2025, and $223.1 million in Q3 2025.